| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 16.96% | Stifel | $11 → $10 | Maintains | Buy |
| 10/11/2023 | 28.65% | Piper Sandler | $8 → $11 | Maintains | Overweight |
| 10/04/2023 | 215.79% | UBS | $29 → $27 | Maintains | Buy |
| 10/04/2023 | 169.01% | Cantor Fitzgerald | $18 → $23 | Maintains | Overweight |
| 10/03/2023 | 104.68% | HC Wainwright & Co. | $16 → $17.5 | Reiterates | Buy → Buy |
| 09/12/2023 | 110.53% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
| 09/07/2023 | 110.53% | Cantor Fitzgerald | → $18 | Reinstates | Overweight → Overweight |
| 08/14/2023 | 110.53% | Cantor Fitzgerald | $22 → $18 | Maintains | Overweight |
| 08/11/2023 | 110.53% | Cantor Fitzgerald | $22 → $18 | Maintains | Overweight |
| 08/11/2023 | -6.43% | Piper Sandler | $48 → $8 | Maintains | Overweight |
| 08/11/2023 | 87.13% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
| 07/24/2023 | 157.31% | Cantor Fitzgerald | → $22 | Reiterates | Overweight → Overweight |
| 05/12/2023 | 250.88% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 03/15/2023 | 239.18% | UBS | $31 → $29 | Maintains | Buy |
| 03/10/2023 | 297.66% | Credit Suisse | $38 → $34 | Maintains | Outperform |
| 03/10/2023 | 250.88% | HC Wainwright & Co. | $65 → $30 | Maintains | Buy |
| 11/09/2022 | 660.23% | HC Wainwright & Co. | $80 → $65 | Maintains | Buy |
| 08/09/2022 | 344.44% | Credit Suisse | $43 → $38 | Maintains | Outperform |
| 06/06/2022 | 87.13% | Stifel | $35 → $16 | Maintains | Buy |
| 05/19/2022 | 461.4% | Piper Sandler | $70 → $48 | Maintains | Overweight |
| 03/01/2022 | 321.05% | Stifel | $60 → $36 | Maintains | Buy |
| 12/22/2021 | 192.4% | Jefferies | $65 → $25 | Downgrades | Buy → Hold |
| 09/30/2021 | 1139.77% | Stifel | → $106 | Initiates Coverage On | → Buy |
| 04/06/2021 | 1022.81% | UBS | → $96 | Initiates Coverage On | → Buy |
| 02/11/2021 | 1046.2% | Credit Suisse | $62 → $98 | Maintains | Outperform |
| 02/10/2021 | 1069.59% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
| 08/11/2020 | 648.54% | Cantor Fitzgerald | → $64 | Initiates Coverage On | → Overweight |
| 08/11/2020 | 543.27% | Piper Sandler | → $55 | Initiates Coverage On | → Overweight |
| 08/11/2020 | 484.8% | Jefferies | → $50 | Initiates Coverage On | → Buy |
| 08/11/2020 | 519.88% | Credit Suisse | → $53 | Initiates Coverage On | → Outperform |
What is the target price for ALX Oncology Holdings (ALXO)?
The latest price target for ALX Oncology Holdings (NASDAQ: ALXO) was reported by Stifel on November 14, 2023. The analyst firm set a price target for $10.00 expecting ALXO to rise to within 12 months (a possible 16.96% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?
The latest analyst rating for ALX Oncology Holdings (NASDAQ: ALXO) was provided by Stifel, and ALX Oncology Holdings maintained their buy rating.
When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?
While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $11.00 to $10.00. The current price ALX Oncology Holdings (ALXO) is trading at is $8.55, which is out of the analyst's predicted range.